Peptide Applications advanced
Peptide Anticancer Agents
Learn about peptide-based anticancer strategies including targeted delivery and apoptosis induction.
By Encyclopeptide Editorial | 1 min read
anticancer oncology targeted-therapy application
Overview
Peptide-based anticancer agents exploit tumor-homing peptides, peptide-drug conjugates, and pro-apoptotic peptides for selective cancer therapy.
Strategies
- Tumor-homing peptides: RGD, NGR motifs targeting tumor vasculature
- Peptide-drug conjugates (PDCs): Targeted cytotoxic delivery
- Pro-apoptotic peptides: Directly triggering tumor cell death
- Checkpoint peptide modulators: Immune activation
Examples
Lutetium-177 DOTATATE (Lutathera) targets somatostatin receptors in neuroendocrine tumors. Melflufen is a peptide-drug conjugate for myeloma.
Clinical Significance
PDCs represent a growing drug class with advantages in tumor penetration and reduced off-target toxicity.
References
- Source: ENCP Peptide Database
- Category: Peptide Applications
Test Your Knowledge
Reinforce what you learned about Peptide Anticancer Agents with interactive quizzes on Wikipept.
Take a Quiz on Wikipept